期刊
IMMUNOLOGICAL REVIEWS
卷 -, 期 -, 页码 -出版社
WILEY
DOI: 10.1111/imr.13253
关键词
autoimmunity; immunotherapies; tumor immunity
类别
Cancer immunotherapy utilizes the host immune system to eradicate tumors, but it also increases the risk of toxicities or immune-related adverse events (irAEs). Recent genome-wide association studies have found genetic associations with irAEs, suggesting a role of germline genetics in their onset. Leveraging germline genetics can help understand and predict the occurrence of irAEs.
Cancer immunotherapy has revolutionized the treatment of advanced cancers and is quickly becoming an option for early-stage disease. By reactivating the host immune system, immunotherapy harnesses patients' innate defenses to eradicate the tumor. By putatively similar mechanisms, immunotherapy can also substantially increase the risk of toxicities or immune-related adverse events (irAEs). Severe irAEs can lead to hospitalization, treatment discontinuation, lifelong immune complications, or even death. Many irAEs present with similar symptoms to heritable autoimmune diseases, suggesting that germline genetics may contribute to their onset. Recently, genome-wide association studies (GWAS) of irAEs have identified common germline associations and putative mechanisms, lending support to this hypothesis. A wide range of well-established GWAS methods can potentially be harnessed to understand the etiology of irAEs specifically and immunotherapy outcomes broadly. This review summarizes current findings regarding germline effects on immunotherapy outcomes and discusses opportunities and challenges for leveraging germline genetics to understand, predict, and treat irAEs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据